Joachim Seipelt is an experienced biotech manager with a strong background in virology and vaccine development. He has experience in research (Boehringer Ingelheim, Max Perutz Labs Vienna), company co-founding (AVIR Green Hills Biotechnology), managing large governmental funding programs (Austria Wirtschaftsservice GmbH), and leading operations at a clinical-stage biotech company (BlueSky Immunotherapies). Proven track record in project management, business development, and academic teaching. Currently, he heads Nuvonis Technologies and advises G.ST Antivirals.